Letter to the editor regarding ‘the plasma metabolome and clinical features of patients with coeliac disease in Northwest China’ Authors: Rijuan Jin Published: 2026 To the Editor We read with great interest the article by Zhang et al. [1] titled ‘The plasma metabolome and clinical features of patients with coeliac disease in Northwest China’. This study conducted plasma metabolomic profiling on 15 patients with celiac disease (CeD) from Northwest China, with comparisons to healthy controls and individuals with inflammatory bowel disease (IBD). Distinctive alterations in the pentose phosphate pathway, tricarboxylic acid cycle, and microbe-associated metabolic pathways were observed in the CeD cohort. As a metabolomic investigation of CeD in a Chinese population, its exploratory value is commendable. Nevertheless, several limitations not explicitly addressed in the original article merit attention, and we offer the following suggestions to enhance its academic rigor. First, the study does not account for medication use among IBD patients, which may compromise the accuracy of the findings. Patients with active IBD frequently receive immunosuppressants, corticosteroids, or biologic agents (e.g. anti-TNF-α monoclonal antibodies). These therapeutics are known to significantly influence metabolomic profiles: corticosteroids alter glucose and lipid metabolic pathways, while biologics such as infliximab modulate inflammation related metabolite levels [2,3]. If the metabolic differences observed in the IBD group stem partly from pharmacological effects rather than from the disease per se, the comparative results between CeD and IBD could be substantially confounded. Moreover, a 2023 Mendelian randomization study has demonstrated causal relationships between specific gut microbiota and metabolites and CeD, identifying metabolites such as phenylacetylglutamine and tryptophan betaine as associated with elevated CeD risk [4]. Whether these metabolites are affected by drug exposure in IBD patients remains systematically unexplored. The inclusion of medication regimens and disease activity indices for IBD participants would substantially strengthen the credibility of the comparative analysis. Second, the diagnostic criteria employed may introduce potential bias. The authors diagnosed CeD following the World Gastroenterology Organisation 2017 guidelines [5], using anti-tTG IgA > 20 CU and Marsh-graded villous atrophy as diagnostic thresholds. However, residents of Northwest China predominantly consume wheat-based staples (e.g. naan and pulled noodles), resulting in high gluten exposure, yet the prevalence of HLA-DQ2/DQ8 haplotypes in this population is lower than in Caucasians [6]. Theoretically, distinct HLA backgrounds may modulate baseline anti-tTG antibody levels; however, internationally validated cutoff values specifically calibrated for Chinese populations remain unavailable. Consequently, direct application of thresholds derived from Western cohorts may introduce diagnostic sensitivity bias—potentially missing atypical presentations or misclassifying individuals with non-canonical HLA genotypes. The inclusion of HLA typing data or stratified reporting of anti-tTG antibody levels across different HLA genotypes in future analyses would substantially augment the validity of the conclusions. Third, the 24-hour dietary recall method adopted in this study carries inherent methodological limitations. Although the authors performed two 24-hour recalls to assess dietary intake and used these data to adjust metabolomic findings, this approach captures only short-term consumption patterns and may not accurately reflect habitual dietary practices [7]. For CeD patients, even without strict adherence to a gluten-free diet, many may unconsciously reduce wheat product intake due to postprandial discomfort. If the two recall days coincidentally fail to capture such ‘spontaneous gluten reduction’, the actual gluten exposure level may be underestimated. Given that the adjustment models heavily depend on the accuracy of dietary recall data, inherent measurement errors and recall bias could compromise the validity of the adjusted results—potentially introducing systematic errors rather than eliminating confounding. Future studies incorporating food-frequency questionnaires or gluten immunogenic peptide detection to enable multidimensional dietary exposure assessments would confer greater robustness to the findings. In summary, Wang et al. have provided an exploratory metabolomic investigation in a Northwest Chinese cohort, contributing to our understanding of metabolic characteristics in Chinese CeD patients. Future research that incorporates the aforementioned variables would help establish a more solid evidentiary foundation for the development of non-invasive diagnostic biomarkers for celiac disease. Acknowledgments Rijuan Jin: Conceptualization, Writing -review & editing, Supervision. All authors have read and approved the final manuscript. Rijuan Jin: Supervision, Writing – review & editing. Funding Statement The author(s) reported there is no funding associated with the work featured in this article. Disclosure statement No potential conflict of interest was reported by the author. Data availability statement Data sharing is not applicable to this article as no new data were created or analyzed in this study. References Associated Data Data Availability Statement Data sharing is not applicable to this article as no new data were created or analyzed in this study.